Literature DB >> 9400998

Induction of Mdm2 and enhancement of cell survival by bFGF.

E Shaulian1, D Resnitzky, O Shifman, G Blandino, A Amsterdam, A Yayon, M Oren.   

Abstract

Basic fibroblast growth factor (bFGF) can exert mitogenic and viability-promoting effects in a wide range of biological systems. The biochemical activities mediating the cell survival function of bFGF are largely unknown. We report here that exposure of fibroblasts to bFGF, which confers upon them increased survival, also causes at the same time an increase in cellular levels of the Mdm2 oncoprotein. Cells constitutively exposed to a bFGF autocrine loop are more refractory to killing by cisplatin. This increased chemoresistance coincides with elevated Mdm2 and reduced activation of the endogenous p53, resulting in inefficient transcriptional activation of the bax gene promoter. Importantly, unlike Mdm2 accumulation in fibroblasts exposed to DNA damage, induction of Mdm2 by bFGF does not occur through a p53-mediated pathway. The role of p53 in DNA damage-induced apoptosis and the ability of Mdm2 to block p53-mediated cell death are well established. These findings therefore suggest that induction of Mdm2 and the subsequent inhibition of p53 function may contribute, at least partially, to the anti-apoptotic effects of bFGF and possibly some other survival factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9400998     DOI: 10.1038/sj.onc.1201453

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Basic fibroblast growth factor in an animal model of spontaneous mammary tumor progression.

Authors:  Steven Kao; Jeffrey Mo; Andrew Baird; Brian P Eliceiri
Journal:  Oncol Rep       Date:  2012-03-07       Impact factor: 3.906

2.  Regulation of MDMX expression by mitogenic signaling.

Authors:  Daniele M Gilkes; Yu Pan; Domenico Coppola; Timothy Yeatman; Gary W Reuther; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

3.  The Mdm2 oncoprotein interacts with the cell fate regulator Numb.

Authors:  T Juven-Gershon; O Shifman; T Unger; A Elkeles; Y Haupt; M Oren
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

4.  Regulation of the mdm2 oncogene by thyroid hormone receptor.

Authors:  J S Qi; Y Yuan; V Desai-Yajnik; H H Samuels
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

5.  Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Authors:  Claire Cole; Sin Lau; Alison Backen; Andrew Clamp; Graham Rushton; Caroline Dive; Cassandra Hodgkinson; Rhona McVey; Henry Kitchener; Gordon C Jayson
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

6.  Overlapping and divergent actions of estrogen and the neurotrophins on cell fate and p53-dependent signal transduction in conditionally immortalized cerebral cortical neuroblasts.

Authors:  S B Wade; P Oommen; W C Conner; D J Earnest; R C Miranda
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

7.  Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.

Authors:  S Song; M G Wientjes; Y Gan; J L Au
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

8.  Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.

Authors:  L Chen; W Lu; S Agrawal; W Zhou; R Zhang; J Chen
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

Review 9.  Polysystic ovary syndrome--loss of the apoptotic mechanism in the ovarian follicles?

Authors:  R Homburg; A Amsterdam
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

10.  The proto-oncogene function of Mdm2 in bone.

Authors:  David J Olivos; Daniel S Perrien; Adam Hooker; Ying-Hua Cheng; Robyn K Fuchs; Jung Min Hong; Angela Bruzzaniti; Kristin Chun; Christine M Eischen; Melissa A Kacena; Lindsey D Mayo
Journal:  J Cell Biochem       Date:  2018-07-16       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.